+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Mandibular reconstruction with transforming growth factor-beta1



Mandibular reconstruction with transforming growth factor-beta1



Laryngoscope 108(3): 368-372



Transforming growth factor-beta1 (TGF-beta1) plus demineralized bone matrix (DBM) will reconstruct a critical mandibular defect devoid of periosteum in a canine model. Randomized, blinded, placebo-controlled, prospective animal pilot study. Canine critical mandibular defects devoid of periosteum were reconstructed with DBM (group 1, n = 3) and DBM plus TGF-beta1 (250 microg TGF-beta1/g DBM) (group 2, n = 3). Radiologic, histologic, and biomechanical testing was performed on the test group and control group specimens at 12 weeks after implantation. A palpable bone bridge was present in the group 2 subjects 5 to 6 weeks after implantation and was never present in the group 1 subjects. Radiologic and histologic examination at the time of harvest (12 weeks after implantation) demonstrated a solid bone bridge in the group 2 subjects and a fibrous union in the group 1 subjects. Group 2 specimens demonstrated failure in four-point bending testing at an average maximum moment of 9.9 +/- 2.2 N-m. This value was 9.4% of the maximum moment of the contralateral nonoperated side. Group 1 specimens were palpably flexible on plate removal and had a biomechanical strength of 0. The difference in strength between group 1 and group 2 was statistically significant (P < 0.02), supporting the hypothesis that the addition of TGF-beta1 to the DBM carrier resulted in the formation of significantly stronger bone in the critical gap. The addition of TGF-beta1 to DBM results in healing of a critical bone defect devoid of periosteum in a higher mammalian model.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 046619954

Download citation: RISBibTeXText

PMID: 9504609


Related references

Adenoviral supply of active transforming growth factor-beta1 (TGF-beta1) did not prevent lethality in transforming growth factor-beta1-knockout embryos. European Cytokine Network 12(4): 561-567, 2002

Transforming growth factor-beta1 induces transforming growth factor-beta1 and transforming growth factor-beta receptor messenger RNAs and reduces complement C1qB messenger RNA in rat brain microglia. Neuroscience 101(2): 313-321, 2000

Effect of IgA aggregates on transforming growth factor-beta1 production in human mesangial cells and the intraglomerular expression of transforming growth factor-beta1 in patients with IgA nephropathy. Korean Journal of Internal Medicine 20(1): 40-47, 2005

Polymorphisms of transforming growth factor-beta1 and transforming growth factor-beta1 type II receptor genes are associated with acute graft-versus-host disease in children with HLA-matched sibling bone marrow transplantation. Bone Marrow Transplantation 30(10): 665-671, 2002

The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 93(12): 5877-5882, 1996

Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Molecular Cancer Research 6(5): 695-705, 2008

Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66(8): 1014-1020, 1998

Effects of hepatocyte growth factor, transforming growth factor-beta1 and epidermal growth factor on bovine corneal epithelial cells under epithelial-keratocyte interaction in reconstruction culture. Experimental Eye Research 66(1): 105-116, 1998

Sequential expression of transforming growth factor beta1 , transforming growth factor beta3 and transforming growth factor alpha in patients with Crohns disease. Gastroenterology 114(4 Part 2): A973, 1998

Increased plasma levels of cystatin C and transforming growth factor-beta1 in patients with coronary artery ectasia: can there be a potential interaction between cystatin C and transforming growth factor-beta1. Coronary Artery Disease 18(3): 211-214, 2007

Hyaluronic acid modulates gene expression of connective tissue growth factor (CTGF), transforming growth factor-beta1 (TGF-beta1), and vascular endothelial growth factor (VEGF) in human fibroblast-like synovial cells from advanced-stage osteoarthritis in vitro. Journal of Orthopaedic Research 28(4): 492-496, 2010

Significance of the overexpression of transforming growth factor alpha, transforming growth factor beta1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. Hepatology 30(4 Part 2): 680A, 1999

Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 19(4): 526-533, 2000

Insulin-like factor of growth (IGFI), insulin-like growth factor binding protein 3 (IGFBP3) and transforming growth factor beta1 (TGF-beta1) in patients with locally-advanced and metastatic cancer of prostate. Voprosy Onkologii 53(5): 544-548, 2007

Concentration of vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) in the serum of patients with cervical cancer: prediction of response. International Journal of Gynecological Cancer 10(2): 151-156, 2000